Insider purchase
Getz Heather C, a director of Myomo, Inc. (NASDAQ:MYO), bought 20,000 shares of common stock on March 16, 2026, at $0.6986 per share. The outlay for the transaction totaled $13,972. Following the acquisition, Getz directly holds 131,754 shares of Myomo.
Market context
Over the seven days prior to the filing, Myomo's shares rose 6.84%, although the stock remains down 87% over the past 12 months. According to InvestingPro analysis cited in company filings, the shares appear undervalued at their current level and the company carries a FAIR financial health rating. The InvestingPro note also references 11 additional tips specific to MYO, covering topics such as cash burn and profitability trends, and mentions a Pro Research Report that spans this company and more than 1,400 U.S. equities.
Recent operating and coverage developments
Myomo reported fourth-quarter revenue of $11.4 million, exceeding Wall Street's estimate of $10.4 million. Despite the revenue beat, the company issued fiscal 2026 guidance that fell short of expectations. In response, Craig-Hallum adjusted its price target on Myomo to $1.10 from $2.00, while keeping a Buy rating on the shares.
Separately, Myomo announced it has entered into network participation agreements with Elevance Health plans. These agreements cover Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans. Management expects the arrangement to add 45 million medical members to Myomo's coverage by the second quarter of 2026, which would bring the total number of covered lives under commercial insurance plans to in excess of 80 million.
Executive compensation changes
To align incentives for 2026, Myomo's CEO Paul Gudonis and CFO David Henry agreed to reduce their base salaries by 10% in exchange for restricted stock units (RSUs). The company's Compensation Committee approved the arrangement. Under the plan, Mr. Gudonis will forgo $40,000 of salary and Mr. Henry will forgo $30,000. The RSUs to be granted in lieu of that portion of cash compensation are valued at 115% of the salary amount foregone.
These RSUs are scheduled to be granted in equal quarterly installments beginning January 2026 and will fully vest three months after each grant date, subject to the executives remaining employed by the company.
Summary analysis
The insider purchase by a sitting director occurs against a backdrop of operational progress in revenue and network expansion, tempered by guidance that disappointed investors and prompted an analyst target reduction. Management has structured a partial shift from cash salary to RSUs for senior executives, reflecting an emphasis on equity-based alignment through 2026.
Key points
- Director Getz Heather C purchased 20,000 Myomo shares on March 16, 2026, for $13,972, now holding 131,754 shares.
- Myomo reported Q4 revenue of $11.4 million, beating estimates, but issued fiscal 2026 guidance below expectations, leading Craig-Hallum to lower its price target to $1.10 from $2.00 while maintaining a Buy rating.
- The company entered network participation agreements with Elevance Health plans expected to add 45 million members by Q2 2026, raising covered commercial lives to over 80 million; senior executives agreed to 10% base salary reductions in 2026 in exchange for RSUs.
Risks and uncertainties
- Fiscal 2026 guidance fell short of expectations, which could continue to pressure sentiment in healthcare-equipment and medtech-related equities.
- Although revenue exceeded estimates for the quarter, durability of revenue and profitability trends remain subject to change, affecting investor confidence.
- The efficacy of network participation agreements in driving utilization and revenue growth is not guaranteed and timing of expected covered lives additions could influence near-term results.
This article presents reported insider activity and company disclosures without forward-looking commentary beyond the statements and figures released by the company and cited analysts.